Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.

Yao GaoJia GuoXuli BaoFang XiongYanpin MaBingqin TanLele YuYong ZhaoJun Lu

Published in: The oncologist (2021)

Autologous iNKT cell treatment is safe and well-tolerated. Expanded iNKT cells produce Th1-like responses with possible antitumor activity. The antitumor effects of iNKT cell infusion in patients with advanced HCC merit further investigation.

Keyphrases

cell therapy
clinical trial
single cell
induced apoptosis
bone marrow
stem cells
mesenchymal stem cells
cell cycle arrest
randomized controlled trial
platelet rich plasma
cell death
open label
oxidative stress
study protocol
phase ii
endoplasmic reticulum stress
smoking cessation